Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer
Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer
Active, not recruiting · NCT03257163 · Registry updated 2026-01-20Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, gastric adenocarcinoma, gastric neoplasm, neoplasm, stomach disorder | Active, not recruiting | Phase 2 | 2026-01-20 | NCT03257163 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| National Cancer Institute (NCI) | 3015 |
| Rutgers, The State University of New Jersey | 154 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Emory University | Atlanta | United States | 33 |
| Montefiore Medical Center | The Bronx | United States | 198 |
| Rutgers Cancer Institute of New Jersey | New Brunswick | United States | 223 |
| RWJBarnabas Health - Robert Wood Johnson University Hospital, Hamilton | Hamilton | United States | 4 |